Sectors
BBOT
BridgeBio Oncology Therapeutics Inc.
9.10
1 x 8.86
1 x 9.16
bid
ask
+
0.38
4.36%
10:01 AM
timesize
| Ytd | -27.32% | |
| 1y | -5.70% |
8.71
day range
9.36
7.00
52 week range
14.87
| Open | 8.72 | Prev Close | 8.72 | Low | 8.71 | High | 9.36 | Mkt Cap | 698.53M |
| Vol | 39.42K | Avg Vol | 439.64K | EPS | -2.01 | P/E | -4.34 | Forward P/E | N/A |
| Beta | 0.39 | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.17 | 200-d Avg | 10.27 | 1yr Est | 24.20 |
| Income Statement | |||
| Operating Expenses | 46.18M | ||
| Research and Development Expense | 39.80M | ||
| Selling, General and Administrative Expense | 6.38M | ||
| Operating Income | -46.18M | ||
| Net Income | -42.11M | ||
| Net Income Common Stock | -42.11M | ||
| Net Income Common Stock (USD) | -42.11M | ||
| Consolidated Income | -42.11M | ||
| Earnings per Basic Share | -526.11 | ||
| Earnings per Basic Share (USD) | -526.11 | ||
| Earnings per Diluted Share | -526.11 | ||
| Earning Before Interest & Taxes (EBIT) | -42.11M | ||
| Earning Before Interest & Taxes (USD) | -42.11M | ||
| Weighted Average Shares | 80.03M | ||
| Weighted Average Shares Diluted | 80.03M | ||
| Balance Sheet | |||
| Cash and Equivalents | 52.79M | ||
| Cash and Equivalents (USD) | 52.79M | ||
| Investments | 336.23M | ||
| Investments Current | 199.62M | ||
| Investments Non-Current | 136.62M | ||
| Trade and Non-Trade Receivables | 146.00K | ||
| Current Assets | 266.50M | ||
| Property, Plant & Equipment Net | 3.16M | ||
| Total Assets | 417.65M | ||
| Debt Current | 538.00K | ||
| Total Debt | 2.64M | ||
| Current Liabilities | 43.26M | ||
| Debt Non-Current | 2.11M | ||
| Total Liabilities | 45.37M | ||
| Accumulated Retained Earnings (Deficit) | -398.67M | ||
| Accumulated Other Comprehensive Income | -981.00K | ||
| Shareholders Equity | 372.28M | ||
| Shareholders Equity (USD) | 372.28M | ||
| Assets Non-Current | 151.14M | ||
| Total Debt (USD) | 2.64M | ||
| Liabilities Non-Current | 2.11M | ||
| Trade and Non-Trade Payables | 12.81M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 186.00K | ||
| Net Cash Flow from Financing | 295.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -321.03M | ||
| Capital Expenditure | -24.00K | ||
| Issuance (Purchase) of Equity Shares | 416.00K | ||
| Net Cash Flow from Investing | -285.41M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -285.38M | ||
| Net Cash Flow from Operations | -35.92M | ||
| Share Based Compensation | 3.87M | ||